Apparently, in BC patients, DLBCL incidence was significantly reduced by tamoxifen treatment (Fisher exact test 0.0168, P < 0.05) compared to aromatase inhibitors or no HT, leading to a 38% reduction in relative risk for the development of DLBCL (Fig. 6 and Supplemental Table 5). The gene discussed is CYP19A1; the disease is breast cancer.